Unity Biotechnology earnings were -$27.9M for the trailing 12 months ending Jun 30, 2024, with N/A growth year over year. The latest UBX earnings report on Jun 30, 2024 announced Q2 2024 earnings of -$5.3M, down 8.8% from last quarter. For the last reported fiscal year 2023 ending Dec 31, 2023, UBX reported annual earnings of -$39.9M, with -10.4% growth. The next UBX earnings date is Nov 11, 2024.
Unity Biotechnology Earnings Reports & History FAQ
What were Unity Biotechnology's earnings last quarter?
On UBX's earnings call on Invalid Date, Unity Biotechnology (NASDAQ: UBX) reported Q2 2024 earnings per share (EPS) of -$0.31, up 71.03% year over year. Total UBX earnings for the quarter were -$5.28 million. In the same quarter last year, Unity Biotechnology's earnings per share (EPS) was -$1.07.
The next UBX earnings call is Invalid Date. Add UBX to your watchlist to be reminded of Unity Biotechnology's next earnings date.
Is Unity Biotechnology profitable or losing money?
As of the last Unity Biotechnology earnings report, Unity Biotechnology is currently losing money. Unity Biotechnology's net profit (also called net income) for the twelve months ending Jun 30, 2024 was -$27.86 million, a 15.98% decrease year over year.
What was UBX's earnings growth in the past year?
As of Unity Biotechnology's earnings date in Invalid Date, Unity Biotechnology's earnings has grown year over year. UBX earnings in the past year totalled -$27.86 million.
What are Unity Biotechnology's earnings expectations?
The current EPS estimate for Unity Biotechnology's earnings report in Invalid Date is -$0.41.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.